Medicare Enrolled
Dr. Moshe Levy, MD
Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Levy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Levy?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Levy
Dr. Moshe Levy is a medical oncology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Levy performed 35,628 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Levy received a total of $4,760,026 from 68 pharmaceutical and/or device companies across 3284 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Levy is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 24% volume in TX
$4,760,026 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗35,628
Medicare services
Top 24% in TX for medical oncology
Not available
Unique patients (not deduplicated)
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
7,260 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 6,900 | $43 | $136 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
4,800 | $0 | $5 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
3,060 | $38 | $127 |
| Paclitaxel chemotherapy injection | 3,037 | $0 | $8 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
2,904 | $0 | $3 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,014 | $0 | $1 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
667 | $10 | $64 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
636 | $8 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
544 | $8 | $36 |
| Anti-nausea injection (Aloxi/palonosetron) | 530 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 510 | $0 | $24 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
487 | $97 | $368 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
217 | $6 | $31 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
196 | $6 | $34 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
195 | $4 | $22 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
189 | $23 | $157 |
| Immunoglobulin light chain measurement A blood test that measures the levels of immunoglobulin light chains, which are proteins produced by plasma cells. |
188 | $17 | $60 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
179 | $13 | $60 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
174 | $62 | $250 |
| Iron level test | 172 | $6 | $27 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
172 | $9 | $35 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
165 | $104 | $707 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 160 | $3 | $373 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
141 | $9 | $56 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
135 | $12 | $108 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
129 | $2 | $300 |
| Reticulated platelet measurement A blood test that measures the level of young, newly formed platelets in the body. |
70 | $35 | $143 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
68 | $7 | $431 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
65 | $51 | $344 |
| Basic metabolic blood panel A blood test that measures a group of basic chemicals, including total calcium levels. |
60 | $8 | $49 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
59 | $1 | $7 |
| Uric acid level test A blood test that measures the level of uric acid in your body. Uric acid is a waste product formed when the body breaks down purines. |
56 | $4 | $25 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
56 | $141 | $496 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
50 | $50 | $313 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
47 | $11 | $96 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
47 | $62 | $247 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
42 | $58 | $211 |
| New patient office visit, complex (60-74 min) | 33 | $162 | $709 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
33 | $1 | $8 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
31 | $94 | $357 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
27 | $48 | $821 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
24 | $177 | $1,067 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
24 | $23 | $161 |
| Automated red blood cell count An automated laboratory test that measures the number of red blood cells in a blood sample. |
21 | $4 | $23 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
20 | $16 | $100 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
20 | $2 | $19 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
14 | $16 | $94 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
1.5% high complexity
86.3% medium
12.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,760,026
Total received (2018-2024)
Avg $680,004/year across 7 years
Top 0% in TX for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
68
Companies
3,284
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$566,834
2023
$775,238
2022
$1,091,773
2021
$1,050,838
2020
$388,471
2019
$490,006
2018
$396,865
Payments by company (2024)
E.R. Squibb & Sons, L.L.C.
$106,345
BeiGene USA, Inc.
$67,087
SOBI, INC
$66,338
Incyte Corporation
$55,898
GlaxoSmithKline, LLC.
$45,310
ABBVIE INC.
$31,296
Takeda Pharmaceuticals U.S.A., Inc.
$27,198
AstraZeneca Pharmaceuticals LP
$24,318
Lilly USA, LLC
$24,156
Amgen Inc.
$20,125
Kite Pharma, Inc.
$19,423
Genmab U.S., Inc.
$18,582
Ipsen Biopharmaceuticals, Inc
$11,310
Janssen Biotech, Inc.
$10,843
Regeneron Pharmaceuticals, Inc.
$8,046
PFIZER INC.
$7,795
Novartis Pharmaceuticals Corporation
$6,480
Adaptive Biotechnologies Corporation
$5,873
GENZYME CORPORATION
$5,126
Geron Corporation
$1,600
Karyopharm Therapeutics Inc.
$1,500
Celgene Corporation
$1,340
Pierre Fabre Pharmaceuticals, Inc.
$211
Eli Lilly and Company
$132
Rigel Pharmaceuticals, Inc.
$85
SERVIER PHARMACEUTICALS LLC
$68
ADC Therapeutics America, Inc.
$63
Blueprint Medicines Corporation
$57
Daiichi Sankyo Inc.
$49
Astellas Pharma US Inc
$31
Merck Sharp & Dohme LLC
$27
Emmaus Medical, Inc.
$26
Agios Pharmaceuticals, Inc.
$25
Legend Biotech USA Inc.
$25
Stemline Therapeutics Inc.
$25
Mirati Therapeutics, Inc.
$21
Top 3 companies account for 42.3% of 2024 payments
All-time payments by company (2018-2024) ›
Seagen Inc.
$1,032,891
Takeda Pharmaceuticals U.S.A., Inc.
$613,458
BeiGene USA, Inc.
$292,235
E.R. Squibb & Sons, L.L.C.
$286,754
Incyte Corporation
$258,499
Amgen Inc.
$192,555
AbbVie, Inc.
$175,501
Karyopharm Therapeutics Inc.
$170,316
AstraZeneca Pharmaceuticals LP
$152,037
Celgene Corporation
$142,258
SOBI, INC
$127,541
GlaxoSmithKline, LLC.
$123,611
Seattle Genetics, Inc.
$119,194
Dova Pharmaceuticals
$105,543
Janssen Biotech, Inc.
$89,006
ABBVIE INC.
$84,226
Epizyme, Inc.,
$78,741
Lilly USA, LLC
$73,523
Kite Pharma, Inc.
$70,453
GENZYME CORPORATION
$70,441
Sobi, Inc
$62,626
AbbVie Inc.
$52,122
JAZZ PHARMACEUTICALS INC.
$43,264
Ipsen Biopharmaceuticals, Inc
$40,397
PharmaEssentia USA Corporation
$31,167
NOVARTIS PHARMACEUTICALS CORPORATION
$30,063
Gilead Sciences, Inc.
$27,691
CTI BioPharma Corp.
$25,754
Novartis Pharmaceuticals Corporation
$24,616
Pharmacyclics LLC, An AbbVie Company
$22,291
Genmab U.S., Inc.
$21,390
Pharmacyclics LLC, an AbbVie Company
$16,627
PFIZER INC.
$15,219
Verastem, Inc.
$14,615
Janssen Scientific Affairs, LLC
$14,487
Genentech USA, Inc.
$14,270
Regeneron Pharmaceuticals, Inc.
$8,046
Adaptive Biotechnologies Corporation
$7,545
Agios Pharmaceuticals, Inc.
$4,859
Spectrum Pharmaceuticals Inc.
$4,502
Eli Lilly and Company
$3,632
MorphoSys, US Inc.
$2,721
Jazz Pharmaceuticals Inc.
$2,200
Blueprint Medicines Corporation
$2,136
Genentech, Inc.
$1,669
Geron Corporation
$1,600
Bayer HealthCare Pharmaceuticals Inc.
$1,195
BeiGene, Ltd.
$975
Astellas Pharma US Inc
$586
Janssen Global Services, LLC
$505
TG THERAPEUTICS, INC.
$450
Secura Bio, Inc.
$349
Rigel Pharmaceuticals, Inc.
$255
Aurobindo Pharma USA, Inc.
$250
SERVIER PHARMACEUTICALS LLC
$225
Pierre Fabre Pharmaceuticals, Inc.
$211
Stemline Therapeutics Inc.
$199
Daiichi Sankyo Inc.
$153
Emmaus Medical, Inc.
$92
ADC Therapeutics America, Inc.
$77
Acrotech Biopharma LLC
$47
RECORDATI_RARE_DISEASES_INC.
$40
Merck Sharp & Dohme LLC
$27
Legend Biotech USA Inc.
$25
Regeneron Healthcare Solutions, Inc.
$25
Mirati Therapeutics, Inc.
$21
Taiho Oncology, Inc.
$14
Acceleron Pharma, Inc.
$13
Top 3 companies account for 40.7% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · ALTUVIIIO · AYVAKIT · Aliqopa · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRUKINSA · Blincyto · CABLIVI · CALQUENCE · Copiktra · DARZALEX · DAURISMO · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EPKINLY · Endari · Epkinly · FARYDAK · Farydak · HEMANGEOL · Hemady · ICLUSIG · IMBRUVICA · INREBIC · Imbruvica · Inrebic · JAKAFI · JAYPIRCA · KEYTRUDA · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LYNPARZA · MONJUVI · NINLARO · Non-Covered Product · OJJAARA · ONUREG · OPDIVO · OXBRYTA · POLIVY · PROMACTA · PYRUKYND · Pomalyst · REBLOZYL · RETEVMO · RYTELO · Reblozyl · Revlimid · Rezlidhia · Rituxan · SARCLISA · SCEMBLIX · SPRYCEL · SYLVANT · TAGRISSO · TASIGNA · TAZVERIK · TECVAYLI · TIBSOVO · Tavalisse · Tazverik · Tibsovo · UKONIQ · VELCADE · VENCLEXTA · VONJO · VYNDAQEL · VYXEOS · Vanflyta · Venclexta · Vonjo · XGEVA · XOSPATA · XPOVIO · Xospata · Yescarta · ZEPZELCA · Zydelig · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Medical oncologists in nearby ZIP areas
90
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Levy is a mixed practice specialist, with above-average Medicare volume (top 24% in TX), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Levy experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Levy performed 7,260 darbepoetin injection (aranesp) for anemia services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Levy receive payments from pharmaceutical companies?
Yes. Dr. Levy received a total of $4,760,026 from 68 companies across 3,284 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Levy's costs compare to other medical oncologists in Dallas?
Dr. Levy's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Levy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Dallas
Browse medical oncologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
BeiGene USA, Inc. Payments to Doctors
See all physicians who received payments from BeiGene USA, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology